子宫内膜癌患者ctDNA检测的预后价值——一项国际多中心研究
该国际多中心研究纳入3个欧洲癌症中心的83例子宫内膜癌患者,术前采集血浆用Oncomine™ Pan-Cancer cell-free assay检测ctDNA,其中56例配对肿瘤组织行全外显子测序。16例(19.3%)ctDNA阳性,阳性与显著更高的复发率相关(37.5% vs 11.9%,P=0.024),校正已知组织病理学危险因素后ctDNA阳性仍为复发的独立预测因子(HR 5.49,95%CI 1.5-20,P=0.010)。
要点
- 术前ctDNA阳性与子宫内膜癌复发率显著升高相关(37.5% vs 11.9%,P=0.024)。
- 校正已知组织病理学危险因素后,ctDNA阳性仍为复发的独立预测因子(HR 5.49,95%CI 1.5-20,P=0.010)。
- 14例复发患者中8例(57%)诊断时ctDNA为阴性。
核心结论
- 使用现成基因面板检测子宫内膜癌患者ctDNA具有可行性,ctDNA阳性与更差的肿瘤学结局显著相关。
研究设计与样本
- 国际多中心队列研究,在3个欧洲癌症中心术前采集83例子宫内膜癌患者的血浆样本。
- 血浆游离DNA(cfDNA)采用Oncomine™ Pan-Cancer cell-free assay分析,83例中56例配对肿瘤组织行全外显子测序,并收集临床资料评估肿瘤学结局。
主要发现
- cfDNA平均投入量为8.17 ng(范围1.47-29.12 ng)。
- 16例(19.3%)患者为ctDNA阳性,携带一个或多个基因的突变;配对病例中血浆检测到的大多数变异与匹配肿瘤中发现的突变一致。
- 术前ctDNA存在与显著更高的复发率相关(37.5% vs 11.9%,P=0.024)。
- 14例复发患者中8例(57%)在诊断时ctDNA为阴性。
- 校正其他已知组织病理学危险因素后,ctDNA阳性仍为复发的独立预测因子(HR 5.49,95%CI 1.5-20,P=0.010)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: At present, no reliable blood-based biomarkers have been established for patients with endometrial cancer. Liquid biopsies, which can detect circulating tumor DNA (ctDNA), provide a non-invasive way to assess prognosis, monitor tumor evolution and treatment response. We aimed to examine the feasibility and performance of ctDNA as a prognostic tool in a multi-center cohort of EC patients with matched tumor samples. METHODS: Blood plasma samples were collected preoperatively from 83 patients at three European cancer centers. Circulating cell-free DNA (cfDNA) was isolated and analyzed using the Oncomine™ Pan-Cancer cell-free assay. Tumor tissue from 56 of the 83 patients was subjected to whole-exome sequencing, and clinical data were collected for oncological outcome assessment. RESULTS: The mean input of cfDNA was 8.17 ng (range 1.47-29.12 ng). Sixteen (19.3 %) patients were considered ctDNA positive with mutations in one or more genes. Most alterations detected in plasma were concordant with mutations found in the matched tumor for the paired cases. The preoperative presence of ctDNA was associated with a significantly higher rate of recurrence (37.5 % vs 11.9 %, P = 0.024). Although eight of the 14 (57 %) patients with recurrence were negative for ctDNA at diagnosis, positive ctDNA status remained an independent predictor of recurrence also when controlling for other known histopathologic risk factors (HR 5.49, 95 % CI 1.5-20, P = 0.010). CONCLUSIONS: Our results demonstrated the feasibility of using an off-the-shelf gene panel to detect ctDNA in patients with endometrial cancer. ctDNA positivity was significantly associated with worse oncological outcomes.
引用
- Lindemann K, Siegenthaler F, Lande KT, et al. Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study. Gynecol Oncol. 2025. PMID: 40081113. doi:10.1016/j.ygyno.2025.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。